Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Frank Bretz & Joel B. Greenhouse. (2023) The Role of Statistical Thinking in Biopharmaceutical Research. Statistics in Biopharmaceutical Research 15:3, pages 458-467.
Read now
Read now
Sue-Jane Wang, Zhipeng Huang & Hai Zhu. (2023) Performance of LTMLE in the Presence of Missing Data in Control-Matched Longitudinal Studies. Statistics in Biopharmaceutical Research 15:3, pages 618-637.
Read now
Read now
Alexei C. Ionan, Miya Paterniti, Devan V. Mehrotra, John Scott, Bohdana Ratitch, Sylva Collins, Shanti Gomatam, Lei Nie, Kaspar Rufibach & Frank Bretz. (2023) Clinical and Statistical Perspectives on the ICH E9(R1) Estimand Framework Implementation. Statistics in Biopharmaceutical Research 15:3, pages 554-559.
Read now
Read now
Noah A. Schuster, Jos W. R. Twisk, Martijn W. Heymans & Judith J. M. Rijnhart. (2023) Causal Mediation Analysis with a Binary Mediator: The Influence of the Estimation Approach and Causal Contrast. Structural Equation Modeling: A Multidisciplinary Journal 30:3, pages 481-490.
Read now
Read now
Camila Olarte Parra, Rhian M. Daniel & Jonathan W. Bartlett. (2023) Hypothetical Estimands in Clinical Trials: A Unification of Causal Inference and Missing Data Methods. Statistics in Biopharmaceutical Research 15:2, pages 421-432.
Read now
Read now
Heinz Schmidli, James H. Roger & Mouna Akacha. (2023) Estimands for Recurrent Event Endpoints in the Presence of a Terminal Event. Statistics in Biopharmaceutical Research 15:2, pages 238-248.
Read now
Read now
Man Jin & Yixin Fang. (2023) Methods for Informative Censoring in Time-to-Event Data Analysis. Statistics in Biopharmaceutical Research 0:0, pages 1-8.
Read now
Read now
Kelly Van Lancker, Sergey Tarima, Jonathan Bartlett, Madeline Bauer, Bharani Bharani-Dharan, Frank Bretz, Nancy Flournoy, Hege Michiels, Camila Olarte Parra, James L. Rosenberger & Suzie Cro. (2023) Estimands and their Estimators for Clinical Trials Impacted by the COVID-19 Pandemic: A Report from the NISS Ingram Olkin Forum Series on Unplanned Clinical Trial Disruptions. Statistics in Biopharmaceutical Research 15:1, pages 94-111.
Read now
Read now
Erin E. Gabriel, Michael C. Sachs & Arvid Sjölander. (2022) Sharp Nonparametric Bounds for Decomposition Effects with Two Binary Mediators. Journal of the American Statistical Association 0:0, pages 1-8.
Read now
Read now
Toshimitsu Hamasaki & Frank Bretz. (2021) Statistics in Biopharmaceutical Research Best Papers Award. Statistics in Biopharmaceutical Research 13:2, pages 129-130.
Read now
Read now
Cornelia Ursula Kunz, Silke Jörgens, Frank Bretz, Nigel Stallard, Kelly Van Lancker, Dong Xi, Sarah Zohar, Christoph Gerlinger & Tim Friede. (2020) Clinical Trials Impacted by the COVID-19 Pandemic: Adaptive Designs to the Rescue?. Statistics in Biopharmaceutical Research 12:4, pages 461-477.
Read now
Read now
Articles from other publishers (26)
Man Jin. (2024) Imputation methods for informative censoring in survival analysis with time dependent covariates. Contemporary Clinical Trials 136, pages 107401.
Crossref
Crossref
Tom Michoel & Jitao David Zhang. (2023) Causal inference in drug discovery and development. Drug Discovery Today 28:10, pages 103737.
Crossref
Crossref
Alex Ocampo & Jemar R. Bather. (2023) Single‐world intervention graphs for defining, identifying, and communicating estimands in clinical trials. Statistics in Medicine 42:21, pages 3892-3902.
Crossref
Crossref
Lou E. Whitehead, Oliver Sailer, Miles D. Witham & James M. S. Wason. (2023) Bayesian borrowing for basket trials with longitudinal outcomes. Statistics in Medicine 42:16, pages 2819-2840.
Crossref
Crossref
Theophile Bigirumurame, Shaun Kuan Wei Hiu, M Dawn Teare, James M S Wason, Andrew Bryant & Matthew Breckons. (2023) Current practices in studies applying the target trial emulation framework: a protocol for a systematic review. BMJ Open 13:6, pages e070963.
Crossref
Crossref
Shasha Han & Xiao‐Hua Zhou. (2023) Defining estimands in clinical trials: A unified procedure. Statistics in Medicine 42:12, pages 1869-1887.
Crossref
Crossref
Margret Erlendsdottir & Forrest W Crawford. (2022) Randomized controlled trials of biomarker targets. Clinical Trials 20:1, pages 47-58.
Crossref
Crossref
Ying Wu, Hongwei Wang, Jie Chen & Hana Lee. 2023. Real-World Evidence in Medical Product Development. Real-World Evidence in Medical Product Development
145
165
.
Jixian Wang, Hongtao Zhang & Ram Tiwari. 2023. Real-World Evidence in Medical Product Development. Real-World Evidence in Medical Product Development
233
254
.
Craig Wang, Yufen Zhang, Fabrizia Mealli & Björn Bornkamp. (2022) Sensitivity analyses for the principal ignorability assumption using multiple imputation. Pharmaceutical Statistics 22:1, pages 64-78.
Crossref
Crossref
James A. Rogers, Hugo Maas & Alejandro Pérez Pitarch. (2022) An introduction to causal inference for pharmacometricians. CPT: Pharmacometrics & Systems Pharmacology 12:1, pages 27-40.
Crossref
Crossref
Victoria Palin, Tjeerd P. Van Staa, Stephanie Steels, Andrea B. Troxel, Rolf H. H. Groenwold, Tom M. MacDonald, David Torgerson, Douglas Faries, Pierre Mancini, Mario Ouwens, Lucy J. Frith, Kate Tsirtsonis, Graham MacLennan & Clementine Nordon. (2022) A first step towards best practice recommendations for the design and statistical analyses of pragmatic clinical trials: A modified Delphi approach. British Journal of Clinical Pharmacology 88:12, pages 5183-5201.
Crossref
Crossref
Chenchen Ma, Xin Shen, Yongming Qu & Yu Du. (2022) Analysis of an incomplete binary outcome dichotomized from an underlying continuous variable in clinical trials. Pharmaceutical Statistics 21:5, pages 907-918.
Crossref
Crossref
Xiaoyan Liu, Chanmin Kim, Zifei Han, Pilar Lim, Satrajit Roychoudhury, Maurizio Fava & Gheorghe Doros. (2022) Assessing treatment benefit in the presence of placebo response using the sequential parallel comparison design. Statistics in Medicine 41:12, pages 2166-2190.
Crossref
Crossref
Yongming Qu & Biyue Dai. (2022) Return‐to‐baseline multiple imputation for missing values in clinical trials. Pharmaceutical Statistics 21:3, pages 641-653.
Crossref
Crossref
Lars Grøvle, Eivind Hasvik & Anne Julsrud Haugen. (2022) Impact of rescue medication in placebo-controlled trials of pharmacotherapy for neuropathic pain and low back pain. Pain 163:3, pages e417-e425.
Crossref
Crossref
Luke Keele & Richard Grieve. (2021) Contrasting approaches for addressing non-adherence in randomized controlled trials: An illustration from the REFLUX trial. Clinical Trials 19:1, pages 97-106.
Crossref
Crossref
Rolf H. H. Groenwold. (2021) Grand Challenge—Crossing Borders to Develop Epidemiologic Methods. Frontiers in Epidemiology 1.
Crossref
Crossref
Jack Bowden, Björn Bornkamp, Ekkehard Glimm & Frank Bretz. (2021) Connecting Instrumental Variable methods for causal inference to the Estimand Framework. Statistics in Medicine 40:25, pages 5605-5627.
Crossref
Crossref
Alex Ocampo, Heinz Schmidli, Peter Quarg, Francesca Callegari & Marcello Pagano. (2021) Identifying treatment effects using trimmed means when data are missing not at random. Pharmaceutical Statistics 20:6, pages 1265-1277.
Crossref
Crossref
Tingyang Ren, Weining Shen, Liwen Zhang & Haibing Zhao. (2021) Bayesian phase II clinical trial design with noncompliance. Statistics in Medicine 40:20, pages 4457-4472.
Crossref
Crossref
Yongming Qu & Ilya Lipkovich. (2021) Implementation of ICH E9 (R1): A Few Points Learned During the COVID-19 Pandemic. Therapeutic Innovation & Regulatory Science 55:5, pages 984-988.
Crossref
Crossref
Björn Bornkamp, Kaspar Rufibach, Jianchang Lin, Yi Liu, Devan V. Mehrotra, Satrajit Roychoudhury, Heinz Schmidli, Yue Shentu & Marcel Wolbers. (2021) Principal stratum strategy: Potential role in drug development. Pharmaceutical Statistics 20:4, pages 737-751.
Crossref
Crossref
Yongming Qu, Linda Shurzinske & Shanthi Sethuraman. (2020) Defining estimands using a mix of strategies to handle intercurrent events in clinical trials. Pharmaceutical Statistics 20:2, pages 314-323.
Crossref
Crossref
Yongming Qu, Junxiang Luo & Stephen J. Ruberg. (2020) Implementation of tripartite estimands using adherence causal estimators under the causal inference framework. Pharmaceutical Statistics 20:1, pages 55-67.
Crossref
Crossref
Man Jin & Guanghan Liu. (2020) Estimand framework: Delineating what to be estimated with clinical questions of interest in clinical trials. Contemporary Clinical Trials 96, pages 106093.
Crossref
Crossref